


Docket No.: PH114205.1701/KM215101.01701
Customer No. 27160



PATENT/OFFICIAL

LIST OF ART CITED BY APPLICANT (PTO-1449)	ATTY. DOCKET NO. 114205.1701	SERIAL NO. 09/832,865
	APPLICANT YU HUA	
	FILING DATE April 12, 2001	GROUP 1633

RECEIVED

APR 03 2002

TECH CENTER 1600/290C

U.S. PATENT DOCUMENTS

Examiner's initials		PATENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>me</i>	A	U.S. 6,187,306B1	13 Feb 2001	Pardoll et al.			
	B	U.S. 5,904,920	18 May 1999	Dranoff et al.			
<i>me</i>	C	U.S. 5,098,702	24 Mar 1992	Zimmerman et al.			
	D	U.S. 5,078,996	7 Jan 1992	Conlon, III et al.			
	E						
	F						

FOREIGN PATENT DOCUMENTS

<i>me</i>	G	WO/92/05262	2 Apr 1992	Johns Hopkins; Frost, P. et al.			
	H	WO/94/04570	3 Mar 1994	Schering Corp.; Heath, A. et al.			
	I	WO/99/43839	2 Sep 1999	Univ. of Pennsylvania; Kim J.J. et al.			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	J	International Search Report PCT/US01/12003	
	K	Fearon et al., "Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response"; Cell, vol. 60, 1990: 397-403.	✓
	L	Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity"; Proc. Natl. Acad. Sci., vol. 90, 1993: 3539-43.	✓
	M	Ridge et al., "A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell"; Nature, vol. 393, 1998: 474-77.	✓
	N	Gunrunathan et al., "CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infections and tumor challenge"; J. Immunol., vol. 161, 1998: 4563-71.	✓
	O	Schrewe et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression"; Mol. Cell. Biol., vol. 10, 1990: 2738-48.	✓
	P	Torres et al., "Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation"; J. Immunol., vol. 148, 1992: 620-26(2).	✓
	Q	Sotomayor et al., "Conversion of Tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40"; Nature Med., vol. 5, 1999: 780-87.	✓
	R	Tan et al., "Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response"; Cancer Gene Therapy, vol. 6, no. 4, 1999: 331-39.	✓
	S	Pape et al., "Direct evidence that functionally impaired CD4+ T-cells persist in vivo following induction of peripheral tolerance"; J. Immunol., vol. 160, no. 10, 1998: 4719-29.	✓
	T	Lode et al., "Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy"; Blood, vol. 91, 1998: 1706-15.	✓
<i>me</i>	U	Mackey, M.F. et al., "Dendritic cells require maturation via CD40 to generate protective antitumor immunity"; J. Immunol., vol. 161, no. 5, 1998: 161-65.	✓
	V		
	W		
	X		
	Y		
	Z		

EXAMINER <i>Phuip Ganga</i>	DATE CONSIDERED <i>4/5/02</i>
--------------------------------	----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.